Evidence map›Paper›PMID 38399230›Full record

ArticlePharmaceutics2024

Identification of Triazolopyrimidinyl Scaffold SARS-CoV-2 Papain-Like Protease (PL

Sebastjan Kralj, Marko Jukič, Miha Bahun, Luka Kranjc, Anja Kolarič, Milan Hodošček, Nataša Poklar Ulrih, Urban Bren

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sebastjan KraljFaculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, SI-2000 Maribor, Slovenia.
Marko JukičFaculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, SI-2000 Maribor, Slovenia.ORCID 0000-0001-6083-5024
Miha BahunBiotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, SI-1000 Ljubljana, Slovenia.
Luka KranjcBiotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, SI-1000 Ljubljana, Slovenia.
Anja KolaričFaculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, SI-2000 Maribor, Slovenia.ORCID 0000-0002-0225-7278
Milan HodoščekNational Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-6728-9318
Nataša Poklar UlrihBiotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-2731-9973
Urban BrenFaculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, SI-2000 Maribor, Slovenia.
University of Ljubljana · SIUniversity of Maribor · SIUniversity of Primorska · SINational Institute of Chemistry · SI

Funding

Slovenian Research And Innovation Agency I0-E015Slovenian Research And Innovation Agency J1-2471Slovenian Research And Innovation Agency J1-4398Slovenian Research And Innovation Agency J1-4414Slovenian Research And Innovation Agency J1-50034Slovenian Research And Innovation Agency J3-4497Slovenian Research And Innovation Agency J3-4498Slovenian Research And Innovation Agency J4-4633Slovenian Research And Innovation Agency J7-4638Slovenian Research And Innovation Agency J7-50043Slovenian Research And Innovation Agency L2-3175Slovenian Research And Innovation Agency L2-4430Slovenian Research And Innovation Agency P1-0403Slovenian Research And Innovation Agency P2-0046Slovenian Research And Innovation Agency P2-0438
6 · The paper itself

Abstract

The global impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its companion disease, COVID-19, has reminded us of the importance of basic coronaviral research. In this study, a comprehensive approach using molecular docking, in vitro assays, and molecular dynamics simulations was applied to identify potential inhibitors for SARS-CoV-2 papain-like protease (PL

Indexed as

antiviral designCADDdrug designHTVSin silico drug designpapain-like proteasePLproprotease inhibitorSARS-CoV-2structure-based designvirtual screening

Identifiers

PMID38399230
PMCPMC10893172
OpenAlexW4391219491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.